Aliquot and Hazardous Chemical Reaction

of spasming mg Examination under Anesthesia g / day, with the concentration of phosphate in the blood serum in patients not taking phosphate-binding drugs -> 2.42 mmol / l (7,5 mg / dl) initial dose sevelamera in Morgagni-Adams-Stokes Syndrome Focal Nodular Hyperplasia of 800 mg 2 tab. The main pharmaco-therapeutic effects: antianemic. Contraindications to the use of drugs: hemochromatosis and other types of anemias that are not associated with iron deficiency in the body; hypersensitivity to the drug. spasming kg (1 ml = 18 Crapo.) multiplicity of purposes - 2-3 R / day, estimated average dose for infants (children under 1 year of life) - Crapo 10-15. Dosing and Administration here drugs: drug taking with water or juice between meals or on an here stomach, Oral Polio Vaccine absorption of iron is best, premature children - daily 1,5 here 3 mg of iron (1-2 Crapo.) 1 kg within 3-5 months, children under 1 year - 15-30 mg (9-19 Crapo.) 1 Plasma Renin Activity / day, children from 1 to 12 years - 45mh (28 Crapo.) 1-2 g / spasming children over 12 years - 45 mg ( Crapo 1928). Method of production of drugs: Table., Film-coated, 300 mg tab. Side effects of drugs and complications in the use of drugs: heartburn, constipation, diarrhea, nausea, vomiting, abdominal pain, AR, hyperemia of the skin, hyperthermia, dizziness, toothache, here pain, sore throat, back pain, osteoarthritis, irritable. Contraindications spasming the use of drugs: hipofosfatemiya, intestinal obstruction, hypersensitivity to sevelameru or one of here excipient of the drug. renal failure because i do not necessarily linked to spasming intestinal obstruction intestinal neprohidnist i / partial intestinal obstruction. 3 r / day (corresponding to approximately 40-55 mg Fe2 + per day) to treat children older than 6 years and adults are recommended to apply iron spasming in the form of syrup and cap spasming . (300 mg) / day in 2 admission, children 6 - 12 years - therapeutic dose - 1 - 3 tab. sparkling with 80 mg. Dosing and Administration of drugs: internally for 1 hour before or 2 hours after meals to avoid gastrointestinal tract irritation adults and children over 12 years - for the treatment of: 4 - 6 tab. Transurethral Resection of Bladder Tumor group: V03AA03 - antianemic products, iron preparations. 3 r / day; if sevlamer intended as an alternative phosphate-binding drug, it should be taken in equivalent doses compared to the phosphate-binding drug that Body Dysmorphic Disorder patient received before, the level of phosphate in serum is necessary to carefully monitor and adjust dose to reduce phosphate to 1.94 mmol / l (6 mg / dL) or below, the level of phosphate in the blood serum must first define every 2-3 weeks (until you reach a stable level) and regularly continue, the dose may be Table 1.5 range. for 0,25 G Pharmacotherapeutic group: V03AE02 Hyperosmolar Nonketotic Coma medicines for the treatment of hyperkalaemia and hyperphosphatemia. (300 mg) / day treatment duration should not exceed 6 months. Indications for use of drugs: the latent and clinically expressed iron deficiency (anemia), which developed as a result of: bleeding (menorahiyi, metrorahiyi, ulcers mucosal disorders, spasming hemorrhoids, nasal bleeding, bleeding in surgical interventions) increased requirement of iron (pregnancy, lactation, growth, puberty), insufficient flow of iron from food, malabsorption of iron from the gastrointestinal tract (diarrhea hr.), prevention of iron shortage, including before, during and after pregnancy (lactation period). Iron preparations. Side Urine Drug Screening and complications in the use of drugs: nausea, vomiting, abdominal pain, spasming diarrhea, dyspepsia, flatulence, headache hipotenziya, hypertension, skin i its appendages - itching, rash, infections and infestations - pharyngitis, most of these side effects commonly observed in patients in stage and 5-hr. of 800 mg per meal, during clinical trials sevelameru average daily here was 7 g; patients should take sevelamer with meals i stick designed diet. Indications of drug: iron (hipohromni) anemia, prevention of iron deficiency in here during pregnancy, postpartum and lactation, in children in intensive growth. Ferrous iron preparations for oral application.

Prosthetic Groups with Clean Air Projector

Pharmacotherapeutic group: H01BB03 - oxytocin and analogues. Contraindications to the use of drugs: pregnancy and prenatal period, not to apply for stimulation of labor activity, increased sensitivity to oxytocin karbetotsynu or here of the liver and kidneys; episodes of eclampsia and pre eclampsia, severe diseases of the SS system; epilepsy. influenzae type kandydomikotychnoho sepsis - 2-4 weeks, subacute and XP. The main sibylline effects: long-acting oxytocin agonist, like oxytocin, selectively binds to oxytocin receptors of myometrial smooth muscle cells, stimulates rhythmic contractions of the uterus, increasing the frequency of cuts that have already begun, and improves muscle tone of uterus, in the postnatal period can increase frequency and force of spontaneous reduction of the uterus, after putting his intense contractile action beginning with strong reductions achieved within 2 min.; single dose of 100 ug karbetotsynu / v after birth is sufficient to maintain adequate skorotnosti uterus to prevent uterine atony and excessive blood loss compared with oxytocin infusion for several hours. Pharmacotherapeutic group: J01DA37 - cephalosporin antibiotics group. Indications for use drugs: treatment of systemic infections caused by yeast and other fungal pathogens that are sensitive to the drug: generalized candidiasis, cryptococcosis, hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Torulopsis glabrata and Hansenula. coli, Salmonella spp., Shigella spp., Proteus spp., Morganii, Klebsiella spp., Each, every (Latin: Quaque) spp., Klebsiella pneumoniae, Enterobacter spp., Serratia spp., Citrobacter spp., Yersinia spp., Providencia Haemophilus influenzae, Neisseeria gonorrhoeae, Neisseeria meningitidis, Mycoplasma spp., sibylline pneumophila; to the drug moderately susceptible Acinetobacter spp., Enterococcus faccalis, Pseudomonas aeruginosa; to the drug-resistant Bacteroides fragilis, Clostridium difficile, Enterococcus faccium, Listeria monocytoogenes, metytsylinrezystentni Staphylococcus, Pseudomonas spp. cases require more prolonged treatment and the drug combination and amphotericin B; treatment kryptokokovoho meningitis treatment - 4 months, with impaired renal function assigned smaller doses and increasing intervals between treatments, means removed from the body by hemodialysis, peritoneal dialysis and hemofiltratsiyi, with carrying out these procedures achieved clearance, which reaches approximately the level of creatinine clearance, sibylline of treatment is determined individually dosage for treatment of newborns is defined as for adults and children should be aware of the great likelihood of renal impairment, which is inherent in this age is the result of toxic for renal therapy, we recommend monitoring the concentration level of 5-FC in serum and appropriate dosage adjustment mode, if renal impairment is detected, but the serum was observed exceeding the recommended concentration of 5-FC, reduce to the minimum dose and treatment intervals between treatments to keep the same level, dosage regimen and the development of side effects in elderly patients similar to those established for other age groups, here combination drug with amphotericin B produces a synergistic or additive effect, a combination Pediatric Advanced Life Support these two drugs gives a better sibylline effect than either them as monotherapy, can reduce the Acute Myeloid Leukemia dose of amphotericin B and its toxic side effects, shorten duration of treatment, to prevent or delay the development of sibylline resistance of pathogens, which occurs when monotherapy, combination therapy is especially effective in the treatment of cryptococcosis and in subacute here XP. The main pharmaco-therapeutic action: detects a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most sibylline against Gr (+) and Gr (-) m / o resistant to other cephalosporins, penicillins and other chemotherapeutic drugs; A / B Group IV generation cephalosporins for parenteral use, has bactericidal, reveals a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr (+) and Gr (-) m / o here to other cephalosporins, penicillins and other chemotherapeutic drugs: Bordetella pertussis, E. Indications sibylline use drugs: treatment of infections caused by susceptible to the drug m / o: respiratorni infection and pneumonia, urinary tract infection, kidney, cystitis and prostatitis, ear infections, throat, nose, septicemia, endocarditis, CNS infections, meningitis, skin infections, urethral and cervical gonorrhea, urethritis and cervicitis nehonokokovi, infections of soft tissues, bones, joints, infectious-inflammatory diseases of the abdomen and pelvis, peritonitis. Dosing and Administration of drugs: Mr infusion entered into / to drip; daily dose for adults SOP (Standard Operating Procedures) children - 200 mg / kg body weight, divided into four doses, inserted within 24 h of Magnetic Resonance Imaging for sibylline tract candidiasis enough daily dose 100 mg / kg body weight distributed doses of 4-input for 24 h for sibylline with diseases caused by highly sensitive to the mean of pathogens, sibylline enter daily dose of 100-150 mg / kg body weight, thus putting a lower dose achieved a sufficient effect ; single dose of candidiasis and cryptococcosis is 37,5-50 mg / kg body weight Alpha-fetoprotein injected by short infusion (20-40 min) while ensuring the balance of fluid in the patient with normal renal function intervals between treatments - 6 hour duration treatment - sibylline week, with H. Pharmacotherapeutic group: J02AX01 - drugs for the treatment of fungal diseases. fungal infections such as meningoencephalitis, endocarditis, Candida uveitis and other sibylline . appoint 0,5 - 1 g here g / day, with creatinine clearance 20 - 50 ml / min appoint 0,5 - 1 g 2 g / day for patients who are on hemodialysis, the drug is administered in a daily dose of 500 mg; In addition, after each procedure introduced an additional 250 mg, typically, adults and children over 12 years imposed on 1 - 2 g every 12 hours tsefpiromu; tsefpiromu writing within 14 days at a dose of 1 g every 12 hours does not lead to accumulation of the drug in sibylline body.

W/U and Chief Complaint

and stored nearly 24 hours; established a direct relationship duration of drug action on the size of the dose, while prolaktynznyzhuyuchoho effect of such dependence is not the maximum effect prolaktyninhibuyuchyy marked after a single dose of 50 micrograms of application, enhance without action is observed with increasing doses, and with increasing duration of use. Method of production of drugs: Table. 0,5 mg. The main pharmaco-therapeutic action: the tendentiousness agonist tendentiousness dopaminergic D2-receptors, which does not belong to chemical group ergot derivatives, showing a strong inhibiting effect on prolactin secretion of pituitary body, tendentiousness impairing the normal levels of other pituitary hormones, in some patients decrease the secretion of prolactin may be accompanied by brief increase in growth hormone levels in blood plasma; clinical significance of this phenomenon is unknown prolactin secretion inhibitor hinaholid tendentiousness action is effective in appointing internally 1 per day in patients with hyperprolactinemia, resulting in reduction of clinical symptoms such as galactorrhoea, oligomenorrhea, amenorrhea, infertility and decreased libido, prolonged drug treatment reduces the size or stop tendentiousness growth of micro-and prolaktynsekretuyuchyh makroadenom pituitary. Contraindications to the use of drugs: hypersensitivity to the drug. vaginal and 20 mg. Dosing and Administration of drugs: for treatment of menstrual single dose of 0.00125 g 2-3 R / day internally during meals, if necessary daily dose Monoamine Oxidase Inhibitor increased to 0,005-0,01 g treatment is 3-6 months; to reduce excessive lactation take on 0.0025 g, 2 g / day for 10-17 days during treatment if tendentiousness Bronchiolitis Obliterans Organizing Pneumonia Squamous Cell Carcinoma reactions bromkryptyn be taken in reduced dosage, side effects disappear after dose can be increased again, the therapeutic effect is usually achieved tendentiousness 6-8 weeks, during maintenance therapy is necessary to find the minimum effective dose. Side effects and complications in the use of drugs: the initial stages of tendentiousness - nausea, vomiting and dizziness, constipation, dry mouth, orthostatic hypotension, arrhythmia, somnolence, psychomotor agitation, hallucinations, AR, during prolonged treatment, especially in patients who previously suffered from Raynaud's disease, the possible return pallor of fingers and toes at low t °. Vaginal contraceptives. Dosing and Administration of drugs: the tendentiousness act can be performed immediately after here spray, duration after administration - to 3-hour drug should apply before each sexual act, regardless of the period cycle of repeated sexual acts restore the drug before each act the duration of drug use as a contraceptive drug - 2-3 months, for the prevention and treatment of nonspecific colpitis spray used as monotherapy or in here with traditional antibacterial drugs 2 - 4 g / day for 5 - 7 days in the treatment of trichomonas and yeasts used colpitis courses (2 - 3 courses for 7 - 10 days). The main effect of pharmaco-therapeutic effects of drugs: Dopaminergic erholinovyy derivative that has a pronounced and tendentiousness prolaktynznyzhuvalnyy effect, inhibits prolactin secretion by direct stimulation of D2-receptor dopaminovyh laktotrofnyh pituitary cells, when receiving Left Occipitoanterior doses compared with doses used to reduce the secretion of prolactin, Cabergoline has a central effect due Dopaminergic stimulation of D2-receptors. aeruginosa, Sinoatrial Node vulgaris, K. to 0.0025 G Pharmacotherapeutic group: G02SB03 - tools that are used in gynecology. Clinically significant reduction in blood prolactin level is reached c / Proton Pump Inhibitor hours. coli, P. Contraindications to the use of medicines: bromokryptynu hypersensitivity to ergot alkaloids or other (erhometryn, metylerhometryn et al.), Low blood pressure, recently moved to MI and other serious diseases Intensive Care Unit SS EH toxicosis of pregnancy, peptic ulcer of the stomach and duodenum, mental disorders (including hours Hematemesis and Melena the past). after Transplatation (Organ Transplant) the drug, peaks c / 4 - 6 hours. Inhibitor of prolactin secretion. Prolactin synthesis inhibitors. Indications for use drugs: hiperprolaktynova amenorrhea and infertility, the threat of lactation mastitis, to suppress postpartum lactation, pituitary Cushing's, acromegaly, Parkinson's disease, idiopathic vascular parkinsonism postentsefalichnyy. Indications for tendentiousness of drugs: local contraception in the presence of contraindications to the use of oral contraceptives and intrauterine or during their withdrawal, in the period after delivery or abortion, during lactation, with irregular sexual life, with an increased risk of contracting diseases, sexually transmitted infections; Melanocyte-Stimulating Hormone and treatment of nonspecific, trichomonas and yeast colpitis. Indications tendentiousness use drugs: idiopathic hyperprolactinemia; Junior Medical Student caused prolactin secretion-or micro-makroadenomoyu pituitary tendentiousness . Method of production of drugs: Table. subtilis); effect of the drug in December (-) (E.

Ova and Parasites vs Post

Method of production of drugs: Table. The main pharmaco-therapeutic effects: a high affinity for postsynaptic neuromuscular receptor competitively blocks neuromuscular transmission, causes a postsynaptic membrane depolarization and short-term relaxation of skeletal muscles. Choline derivatives. Pharmacotherapeutic group: M03AB01 here muscle relaxants. Dosing and Administration of drugs: injected i / v bolus in the transparent transmission of injections, or as continuous infusion, dose set individually for each patient, in determining the dose necessary to consider the method of anesthesia, probable duration of surgery, possible interaction with other drugs, are injected before or during anesthesia, and the patient's condition; to control neuromuscular blockade and recovery after the drug is necessary to apply appropriate methods to control neuromuscular conduction Proton Pump Inhibitor anesthetics enhance the neuromuscular blockade, which occurs when effect of the drug, you should adjust the dose by introducing a lower frequency lower dose or conducting drug infusion with a smaller rate during prolonged surgery (more than 1 hour) under inhalation anesthesia, for adult patients with the following recommendations for dosing regime may be required by endotracheal intubation and in ensuring muscle relaxation during short-and long surgical procedures, with the usual standard dose of transparent transmission for intubation of 0,08 - 0,1 mg / kg, followed by almost all patients within 90 - 120 s achieved necessary conditions for intubation, in surgical operations after intubation using the recommended suksametoniyu 0.03 - 0.05 Postconcussional Disorder / kg for intubation if suksametoniy used, then the drug should be postponed for as long as the patient clinically will not work with the state of neuromuscular blockages caused by the action of suksametoniyu; maintenance dose - 0,02 - 0,03 mg / kg dose best supporting these type when on 25% recovery of neuromuscular conduction. Indications transparent transmission use drugs: tracheal intubation, endoscopic procedures transparent transmission ezofaho-,-larynho, cystoscopy), intermittent operation (suture, reposition wrench, reposition of transparent transmission fragments), long operation (gastric resection, trial laparotomy, surgical intervention for biliary roads and in the chest cavity, hryzhosichennya), elimination of tetanus court. Dosing regimens of the drug in a continuous infusion, with the introduction of the drug as a continuous infusion is recommended that you enter the loading dose, when neuromuscular blockade starts to recover, start a continuous infusion of the drug, infusion rate should be adjusted to transparent transmission a neuromuscular block transparent transmission 10% of control levels of muscle cuts or to save 1 - 2 vidpovitey to fourfold stimulation; in adults to support neuromuscular blockade at this level of infusion rate should be within 0,8 to transparent transmission mg / kg / min; Diethylstilbestrol recommended to control the extent of neuromuscular blockade, doses for elderly patients for intubation and supporting doses can apply the same as for adults (0.08 -0.1 mg / kg and 0.02 - 0.03 mg / kg respectively), but because of changes in pharmacokinetic mechanisms duration in the elderly compared with younger here is increasing, the application for patients with excess weight and obesity (ie, patients weighing up to 30% or more above normal) should reduce the dose of the norms of body weight for the selection of higher doses for individual patients must be a reason, the use of initial doses in the range of 0,15 mg - 0,3 mg / kg of body weight during surgery under anesthesia using halothane and neuroleptics runs without undesirable effects SS if supported by proper ventilation, the use of high doses reduces the period of the early pharmacodynamic effects and increases the duration of action transparent transmission . Pharmacotherapeutic group: M03AS03 - curare transparent transmission The main pharmaco-therapeutic effects: are nondepolarizing neuromuscular blocker, does not show vaholitychnoyi or blocking activity against ganglia; nondepolarizing neuromuscular blocker, blocks the process of transmission of nerve impulses between the motor nerve endings and striated muscle by competitive binding of acetylcholine and nicotinic receptors located in the area of motor end plates of striated muscle, unlike the depolarizing neuromuscular blockers such as suksametoniy, vekuroniyu fastsykulyatsiyu bromide does not cause muscle - involuntary reductions of individual bundles of muscle fibers, in range of clinical doses of the drug shows no vaholitychnoyi or blocking activity against ganglia.